.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Health officials in British Columbia recently confirmed that a Canadian tested positive for the Andes strain hantavirus. This individual returned from a luxury cruise ship, the MV Hondius, which experienced a significant viral outbreak. Currently, the patient remains in stable condition at a hospital in Victoria. While the situation involves specific travel history, it highlights the importance of monitoring viral hemorrhagic fevers globally. Furthermore, the quick response of provincial authorities prevented community exposure.
The Andes strain of hantavirus is particularly concerning due to its unique clinical profile. Unlike many other hantaviruses, this specific strain can transmit between humans in rare instances. Moreover, the World Health Organization notes that it can cause severe pulmonary illness. Because this strain carries a fatality rate of up to 50%, medical professionals must maintain high vigilance during outbreaks. However, health authorities currently maintain that the risk to the general public remains low.
The infected individual belongs to a group of four people who recently traveled on a polar expedition. Consequently, B.C. health officials isolated the group upon their arrival to prevent potential transmission. Since Yukon lacks specific testing facilities, clinicians transferred the individuals to Victoria for specialized care. Additionally, Dr. Bonnie Henry confirmed that the group had no contact with the public during their transfer. This proactive approach ensures that the virus does not spread within the community. Medical teams continue to monitor all exposed individuals for symptoms.
Q1: How does the Andes strain differ from other hantaviruses?
While most hantaviruses spread via rodent contact, the Andes strain can occasionally transmit from person to person. It also causes severe respiratory distress.
Q2: What was the source of this specific outbreak?
The outbreak originated on the MV Hondius cruise ship during a polar expedition that departed from Argentina in April 2026.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A Canadian has tested positive for the Andes strain of hantavirus following an outbreak on the MV Hondius cruise ship. Risk of public spread remains low....
3 months ago
Explore the emerging role of Brixadi, an extended-release buprenorphine injection, for managing stimulant use disorder through kappa opioid receptor antagonism and steady plasma levels.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
